Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

By Brian Moy | Sep 7, 2018 | 4:45 PM GMT

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores